Search Results

You are looking at 51 - 60 of 289 items for :

  • "neutropenia" x
Clear All
Full access

-897 ), the first node in the “Yes” pathway for “Significant concerns about alopecia or neutropenia” should have read, “Platinum/ pemetrexed + bevacizumab” (page 894). The editorial office apologizes for this error. A corrected copy of the editorial is

Full access

Jeffrey Crawford

, the NCCN Guidelines Panel initially established the febrile neutropenia threshold for use of myeloid growth factors at 20%; this standard has now been adopted by virtually all other guidelines committees. Moreover, it was the NCCN Panel who stressed

Full access

.0021 Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules Althaus Betsy L. PharmD, BCOP 02 2007 5 5 2 2 229 229 234 234 0050229 10.6004/jnccn.2007.0022 Antibacterial

Full access

389 389 10.6004/jnccn.2004.0032 Fever and Neutropenia Clinical Practice Guidelines in Oncology 9 2004 2 2 5 5 390 390 390 390 10.6004/jnccn.2004.0033 Point: Fluoroquinolone-Based Antibacterial Chemoprophylaxis in Neutropenic Cancer Patients Works

Full access

Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma and Dorothy A. Shead

Infectious diseases are important causes of morbidity and mortality in patients with cancer. In certain instances, the malignancy itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized for many decades as a major

Full access

Gary H. Lyman

patients with breast cancer showed that the biosimilar filgrastim was equally effective as the reference product in the prevention of neutropenia in patients receiving myelosuppressive chemotherapy. 3 Filgrastim-sndz was subsequently approved for the

Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat and Qian Zhang

: Panobinostat is associated with a substantially higher odds of anemia, thrombocytopenia, fatigue and diarrhea. However, it has a 75% lower risk of neutropenia and 10% lower risk of grade 3 and 4 complications. Figure 1 Odds ratio of grade 3 and grade 4

Full access

Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung and Taewoong Choi

-free melphalan and thirty-six received generic melphalan; both groups had similar demographics, performance status and ISS stage ( Table 1 ). There was no statistically significant difference in time to count recovery, toxicities (mucositis, febrile neutropenia

Full access

Philip E. Lammers and Leora Horn

years) had improved median PFS and RR but no improvement in median OS. 11 The most common grade 3 or higher AEs in the bevacizumab arm were neutropenia (26%), hypertension (7%), febrile neutropenia (5%), and bleeding events (4%). 9 Compared with

Full access

Jeremy Lund, Angela Pearson and Georgia Keriazes

readmitting diagnosis or ICD-9 code. Criteria for CRR included diagnosis of febrile neutropenia, other known toxicity of administered chemotherapy agent, and documented diagnosis of CRR by the oncologist. A multidisciplinary panel (medical oncologist, oncology